MA50034A - Composition de stimulation ovarienne contrôlée - Google Patents

Composition de stimulation ovarienne contrôlée

Info

Publication number
MA50034A
MA50034A MA050034A MA50034A MA50034A MA 50034 A MA50034 A MA 50034A MA 050034 A MA050034 A MA 050034A MA 50034 A MA50034 A MA 50034A MA 50034 A MA50034 A MA 50034A
Authority
MA
Morocco
Prior art keywords
composition
ovarian stimulation
controlled ovarian
controlled
stimulation
Prior art date
Application number
MA050034A
Other languages
English (en)
Other versions
MA50034B1 (fr
Inventor
Saez Joan-Carles Arce
Lisbeth Helmgaard
Bjarke Mirner Klein
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MA50034A publication Critical patent/MA50034A/fr
Publication of MA50034B1 publication Critical patent/MA50034B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA50034A 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée MA50034B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17189119 2017-09-01
PCT/EP2018/073442 WO2019043143A1 (fr) 2017-09-01 2018-08-31 Composition destinée à la stimulation ovarienne contrôlée

Publications (2)

Publication Number Publication Date
MA50034A true MA50034A (fr) 2021-05-12
MA50034B1 MA50034B1 (fr) 2022-02-28

Family

ID=59772482

Family Applications (2)

Application Number Title Priority Date Filing Date
MA056224A MA56224A (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée
MA50034A MA50034B1 (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA056224A MA56224A (fr) 2017-09-01 2018-08-31 Composition de stimulation ovarienne contrôlée

Country Status (30)

Country Link
US (2) US11744879B2 (fr)
EP (2) EP3973982A1 (fr)
JP (2) JP6856819B2 (fr)
KR (1) KR20200045543A (fr)
CN (1) CN111050787A (fr)
AR (1) AR112541A1 (fr)
AU (1) AU2018326556A1 (fr)
BR (1) BR112020003379A2 (fr)
CA (1) CA3073624A1 (fr)
CL (1) CL2020000482A1 (fr)
DK (1) DK3675894T3 (fr)
EA (1) EA202090480A1 (fr)
ES (1) ES2904787T3 (fr)
HR (1) HRP20211802T1 (fr)
HU (1) HUE056726T2 (fr)
IL (1) IL272763B2 (fr)
JO (1) JOP20200034A1 (fr)
LT (1) LT3675894T (fr)
MA (2) MA56224A (fr)
MD (1) MD3675894T2 (fr)
MX (1) MX2020002235A (fr)
PH (1) PH12020500404A1 (fr)
PL (1) PL3675894T3 (fr)
PT (1) PT3675894T (fr)
RS (1) RS62810B1 (fr)
SG (1) SG11202003840QA (fr)
SI (1) SI3675894T1 (fr)
TW (1) TWI749255B (fr)
UA (1) UA126869C2 (fr)
WO (1) WO2019043143A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202237173A (zh) * 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0107881A (pt) * 2000-01-27 2003-04-01 Applied Research Systems Uso de fsh tratamento de infertilidade
US20040248784A1 (en) 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
CA2700335C (fr) * 2007-09-21 2015-12-01 Pharmabrand S.A. Composition comportant des polysaccharides mucilagineux derives de alde barbadensis combines a des liposomes, methode pour l'obtenir et utilisation de celle-ci comme ecran solaire, agent anti-acne, regenerateur d'epiderme ou hydratant
TWI488640B (zh) 2008-04-16 2015-06-21 Ferring Int Ct Sa 藥學製劑
EP2526111A2 (fr) * 2010-01-21 2012-11-28 Ramot at Tel Aviv University, Ltd. Dérivés d'aloé-émodine et leur utilisation pour le traitement du cancer
PL2621517T5 (pl) 2010-09-29 2024-01-29 Ferring B.V. Kompozycja do stosowania w leczeniu niepłodności
WO2012168680A1 (fr) 2011-06-06 2012-12-13 Ferring B.V. Préparation pharmaceutique
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
SG11201608132UA (en) * 2014-04-18 2016-11-29 Glycotope Gmbh Controlled ovarian hyperstimulation with improved recombinant human follicle-stimulating hormone
AU2016223496B2 (en) 2015-02-26 2021-09-09 Ferring B.V. Methods of treating infertility
US10660938B2 (en) * 2015-04-17 2020-05-26 Ferring B.V. Recombinant FSH composition for treatment of infertility
WO2016170113A1 (fr) 2015-04-24 2016-10-27 Ferring B.V. Procédé de production de gonadotrophine
RU2719468C2 (ru) 2015-06-26 2020-04-17 Ферринг Б.В. Способы очистки и/или вирусной инактивации
TW201945024A (zh) 2018-04-30 2019-12-01 荷蘭商菲林公司 用於經控制之卵巢刺激的組成物
KR20210079276A (ko) 2018-10-17 2021-06-29 훼링 비.브이. 제어된 난소 자극을 위한 조성물 및 방법

Also Published As

Publication number Publication date
HUE056726T2 (hu) 2022-03-28
CL2020000482A1 (es) 2020-06-26
TW201919687A (zh) 2019-06-01
US20240024424A1 (en) 2024-01-25
SI3675894T1 (sl) 2022-01-31
AR112541A1 (es) 2019-11-06
PH12020500404A1 (en) 2021-03-01
LT3675894T (lt) 2021-12-10
PL3675894T3 (pl) 2022-02-21
EP3675894B1 (fr) 2021-11-03
IL272763A (en) 2020-04-30
EA202090480A1 (ru) 2020-07-20
IL272763B1 (en) 2023-10-01
UA126869C2 (uk) 2023-02-15
EP3973982A1 (fr) 2022-03-30
MA56224A (fr) 2022-04-20
ES2904787T3 (es) 2022-04-06
MX2020002235A (es) 2020-07-20
AU2018326556A1 (en) 2020-03-05
US20200197493A1 (en) 2020-06-25
EP3675894A1 (fr) 2020-07-08
MA50034B1 (fr) 2022-02-28
HRP20211802T1 (hr) 2022-03-04
RS62810B1 (sr) 2022-02-28
JOP20200034A1 (ar) 2020-02-13
TWI749255B (zh) 2021-12-11
JP2020528071A (ja) 2020-09-17
US11744879B2 (en) 2023-09-05
CA3073624A1 (fr) 2019-03-07
WO2019043143A1 (fr) 2019-03-07
CN111050787A (zh) 2020-04-21
DK3675894T3 (da) 2022-01-24
JP7373479B2 (ja) 2023-11-02
SG11202003840QA (en) 2020-05-28
JP6856819B2 (ja) 2021-04-14
PT3675894T (pt) 2022-01-25
KR20200045543A (ko) 2020-05-04
JP2021046398A (ja) 2021-03-25
BR112020003379A2 (pt) 2020-08-25
IL272763B2 (en) 2024-02-01
MD3675894T2 (ro) 2022-03-31

Similar Documents

Publication Publication Date Title
IL272888A (en) Uses of piperidinyl-indole derivatives
DK3697376T3 (da) Sammensætning
DK3331876T3 (da) Modulators of ror-gamma
DK3377516T3 (da) Sammensætning til behandling af cancer
FR3021533B1 (fr) Composition cosmetique de type gel
IL269409A (en) Combinations of chk1- and wee1 - inhibitors
IL268731A (en) New uses of anti-SIRPG antibodies
MA43134A (fr) Compositions et méthodes de transduction tumorale
DK3283210T3 (da) Fremgangsmåde
MA51337A (fr) Inhibiteurs spiro exo-aza de l'interaction ménine-mll
GB2555968B (en) Controlled activation of extended-life cement compositions
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner
EP3484444C0 (fr) Composition d'émulsion de pickering
DK3638293T3 (da) Sammensætninger til behandling af cancer
GB201709958D0 (en) Heterocyclic small molecule modulators of human STING
MA50034A (fr) Composition de stimulation ovarienne contrôlée
FR3025098B1 (fr) Composition cosmetique de type gel facilement demaquillable
ES1209313Y (es) Composicion liofilizada
DK3548006T3 (da) Sammensætning til behandling af tarmforandringer
MA43166A (fr) Formulation de fviii
DK3285588T3 (da) Fremgangsmåde
MA53909A (fr) Compositions et méthodes de stimulation ovarienne contrôlée
SG11202105136WA (en) Application of chidamide
DK3470482T3 (da) Coatingsammensætning
DK3582764T3 (da) Behandling af alkoholisme